Myriad's Q2 Revenues Increase 21 Percent; New $200M Stock Buyback Program Launched | GenomeWeb

NEW YORK (GenomeWeb News) – Myriad Genetics' fiscal second-quarter revenues increased 21 percent year over year, the Salt Lake City firm reported after the close of the market on Tuesday.

Total revenues for the three months ended Dec. 31, 2012 came in at $149.1 million, up from $122.8 million in the year ago period, and beating the average analyst estimate of $143.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.